Last reviewed · How we verify
Loqtorzi (TORIPALIMAB)
Loqtorzi blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells.
Loqtorzi (toripalimab) is a monoclonal antibody that targets the PD-1 receptor, classified as a Programmed Death Receptor-1 Blocking Antibody. It is developed by Coherus Biosciences Inc and approved by the FDA in 2024 for the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC) and recurrent unresectable or metastatic NPC. Loqtorzi works by blocking the PD-1 receptor, allowing the immune system to recognize and attack cancer cells. It is currently patented and its commercial status is not yet generic. Key safety considerations include potential immune-related adverse events.
At a glance
| Generic name | TORIPALIMAB |
|---|---|
| Sponsor | Coherus Biosciences Inc |
| Drug class | Programmed Death Receptor-1 Blocking Antibody [EPC] |
| Target | Pd-1 |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2024 |
Mechanism of action
Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Toripalimab-tpzi is a humanized IgG4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
Approved indications
- metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC)
- recurrent unresectable or metastatic NPC
Common side effects
- nausea
- vomiting
- decreased appetite
- constipation
- hypothyroidism
- rash
- pyrexia
- diarrhea
- peripheral neuropathy
- cough
- musculoskeletal pain
- upper respiratory infection
Key clinical trials
- The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer (PHASE3)
- Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma (NA)
- Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line (PHASE2)
- A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors (PHASE1)
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1,PHASE2)
- Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC (PHASE2)
- Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients (PHASE2)
- Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
| Biologic Exclusivity |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Loqtorzi CI brief — competitive landscape report
- Loqtorzi updates RSS · CI watch RSS
- Coherus Biosciences Inc portfolio CI